BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chouaki Benmansour N, Carvelli J, Vivier E. Complement cascade in severe forms of COVID-19: Recent advances in therapy. Eur J Immunol 2021;51:1652-9. [PMID: 33738806 DOI: 10.1002/eji.202048959] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
Number Citing Articles
1 Agostinis C, Mangogna A, Balduit A, Aghamajidi A, Ricci G, Kishore U, Bulla R. COVID-19, Pre-Eclampsia, and Complement System. Front Immunol 2021;12:775168. [PMID: 34868042 DOI: 10.3389/fimmu.2021.775168] [Reference Citation Analysis]
2 Al-Gburi S, Beissert S, Günther C. Molecular mechanisms of vasculopathy and coagulopathy in COVID-19. Biol Chem 2021;402:1505-18. [PMID: 34657406 DOI: 10.1515/hsz-2021-0245] [Reference Citation Analysis]
3 Bunprakob S, Hemachudha P, Ruchisrisarod C, Supharatpariyakorn T, Hemachudha T. IP-10 and complement activation as friend or foe in COVID-19. Int J Immunopathol Pharmacol 2022;36:039463202210962. [DOI: 10.1177/03946320221096202] [Reference Citation Analysis]
4 El Sissy C, Saldman A, Zanetta G, Martins PV, Poulain C, Cauchois R, Kaplanski G, Venetz JP, Bobot M, Dobosziewicz H, Daniel L, Koubi M, Sadallah S, Rotman S, Mousson C, Pascual M, Frémeaux-Bacchi V, Fakhouri F. COVID-19 as a potential trigger of complement-mediated atypical HUS. Blood 2021;138:1777-82. [PMID: 34482396 DOI: 10.1182/blood.2021012752] [Reference Citation Analysis]
5 Kaivola J, Nyman TA, Matikainen S. Inflammasomes and SARS-CoV-2 Infection. Viruses 2021;13:2513. [PMID: 34960782 DOI: 10.3390/v13122513] [Reference Citation Analysis]
6 Ort M, Dingemanse J, Hsin CH, Richard M, Huehn E, Sabattini G, van de Wetering J, Kornberger R, van den Anker J, Kaufmann P. First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients. Basic Clin Pharmacol Toxicol 2022. [PMID: 35596117 DOI: 10.1111/bcpt.13756] [Reference Citation Analysis]
7 Deravi N, Ahsan E, Fathi M, Hosseini P, Yaghoobpoor S, Lotfi R, Pourbagheri-Sigaroodi A, Bashash D. Complement inhibition: A possible therapeutic approach in the fight against Covid-19. Rev Med Virol 2021;:e2316. [PMID: 34873779 DOI: 10.1002/rmv.2316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bobcakova A, Barnova M, Vysehradsky R, Petriskova J, Kocan I, Diamant Z, Jesenak M. Activated CD8+CD38+ Cells Are Associated With Worse Clinical Outcome in Hospitalized COVID-19 Patients. Front Immunol 2022;13:861666. [DOI: 10.3389/fimmu.2022.861666] [Reference Citation Analysis]
9 Georg P, Astaburuaga-García R, Bonaguro L, Brumhard S, Michalick L, Lippert LJ, Kostevc T, Gäbel C, Schneider M, Streitz M, Demichev V, Gemünd I, Barone M, Tober-Lau P, Helbig ET, Hillus D, Petrov L, Stein J, Dey HP, Paclik D, Iwert C, Mülleder M, Aulakh SK, Djudjaj S, Bülow RD, Mei HE, Schulz AR, Thiel A, Hippenstiel S, Saliba AE, Eils R, Lehmann I, Mall MA, Stricker S, Röhmel J, Corman VM, Beule D, Wyler E, Landthaler M, Obermayer B, von Stillfried S, Boor P, Demir M, Wesselmann H, Suttorp N, Uhrig A, Müller-Redetzky H, Nattermann J, Kuebler WM, Meisel C, Ralser M, Schultze JL, Aschenbrenner AC, Thibeault C, Kurth F, Sander LE, Blüthgen N, Sawitzki B; PA-COVID-19 Study Group. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell 2022;185:493-512.e25. [PMID: 35032429 DOI: 10.1016/j.cell.2021.12.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
10 Ameratunga R, Woon ST, Steele R, Lehnert K, Leung E, Brooks AES. Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2. Expert Rev Clin Immunol 2022. [PMID: 35510369 DOI: 10.1080/1744666X.2022.2074403] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 deKay JT, Emery IF, Rud J, Eldridge A, Lord C, Gagnon DJ, May TL, Herrera VLM, Ruiz-Opazo N, Riker RR, Sawyer DB, Ryzhov S, Seder DB. DEspRhigh neutrophils are associated with critical illness in COVID-19. Sci Rep 2021;11:22463. [PMID: 34789851 DOI: 10.1038/s41598-021-01943-7] [Reference Citation Analysis]
12 Leatherdale A, Stukas S, Lei V, West HE, Campbell CJ, Hoiland RL, Cooper J, Wellington CL, Sekhon MS, Pryzdial ELG, Conway EM. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality. Med Microbiol Immunol 2022. [PMID: 35034207 DOI: 10.1007/s00430-021-00725-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]